• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低度恶性 PMP 是否可以根据组织学特征分为预后不同的亚组?一项回顾性研究及使用恰当分类的重要性。

Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification.

机构信息

Department of Surgical Oncology, Fortis Hospital, Bangalore, India.

Department of Pathology, Fortis Hospital, Bangalore, India.

出版信息

Eur J Surg Oncol. 2018 Jul;44(7):1105-1111. doi: 10.1016/j.ejso.2018.03.032. Epub 2018 Apr 12.

DOI:10.1016/j.ejso.2018.03.032
PMID:29685759
Abstract

INTRODUCTION

The pathological classification of PMP of appendiceal origin has prognostic and treatment implications. Our goals were to • Classify low grade mucinous carcinoma peritonei (LGMCP) into prognostically distinct subgroups based on histological features. • Compare the reproducibility of the WHO and the PSOGI classifications for both PMP and the appendiceal primary tumor.

PATIENTS AND METHODS

A retrospective analysis of patients undergoing CRS and HIPEC or debulking surgery was done. All the tumors were re-classified according to the PSOGI classification. LGMCP was further classified into three histological subgroups and the impact on survival was evaluated.

RESULTS

From Jun 2011 to June 2016, 101 patients underwent CRS with HIPEC (n = 89) or debulking surgery (n=12). The median PCI was 28 (3-39) and 74.1% patients had CC-0/1 resections. Of the 76.2% patients who had LGMCP, 4 patients (5.1%) were classified as group 1, 54 (70.1%) as group 2 and 19 patients (24.6%) as group 3. At a median follow up of 21 months, the disease free survival was not reached, 30 months and 14 months for groups 1, 2 and 3 respectively (p = 0.09). There was no difference in overall survival. Using the WHO classification, there was a discordance in the grade of the primary tumor and the peritoneal lesions in 19.8% and conflicting terminology was used in 62% of patients.

CONCLUSIONS

The subgroups of LGMCP described here are prognostically different though this needs further prospective evaluation in larger series. The PSOGI classification is more uniformly reproducible and should be preferred to the WHO classification.

摘要

简介

阑尾来源的 PMP 的病理分类具有预后和治疗意义。我们的目标是:

  1. 根据组织学特征将低级别黏液性腹膜癌(LGMCP)分为预后不同的亚组。

  2. 比较 WHO 和 PSOGI 分类对 PMP 和阑尾原发性肿瘤的可重复性。

患者和方法

对接受 CRS 和 HIPEC 或减瘤手术的患者进行了回顾性分析。所有肿瘤均根据 PSOGI 分类重新分类。进一步将 LGMCP 分为三个组织学亚组,并评估其对生存的影响。

结果

2011 年 6 月至 2016 年 6 月,101 例患者接受了 CRS 联合 HIPEC(n=89)或减瘤手术(n=12)。中位 PCI 为 28(3-39),74.1%的患者行 CC-0/1 切除。在 76.2%的 LGMCP 患者中,4 例(5.1%)患者为 1 组,54 例(70.1%)为 2 组,19 例(24.6%)为 3 组。中位随访 21 个月时,1 组、2 组和 3 组的无疾病生存率分别为未达到、30 个月和 14 个月(p=0.09)。总生存率无差异。使用 WHO 分类,原发性肿瘤和腹膜病变的分级存在差异的比例为 19.8%,使用的术语不一致的比例为 62%。

结论

这里描述的 LGMCP 亚组具有不同的预后,但这需要在更大的系列中进一步前瞻性评估。PSOGI 分类更具一致性,应优先于 WHO 分类。

相似文献

1
Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification.低度恶性 PMP 是否可以根据组织学特征分为预后不同的亚组?一项回顾性研究及使用恰当分类的重要性。
Eur J Surg Oncol. 2018 Jul;44(7):1105-1111. doi: 10.1016/j.ejso.2018.03.032. Epub 2018 Apr 12.
2
Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.对接受细胞减灭术和腹腔热灌注化疗治疗的 265 例患者的单中心系列进行的最近的 PSOGI 病理分类对假性黏液瘤腹膜的验证。
Ann Surg Oncol. 2018 Feb;25(2):404-413. doi: 10.1245/s10434-017-6252-1. Epub 2017 Nov 20.
3
Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.阑尾外源性腹膜假黏液瘤:一项对比研究。
Ann Surg Oncol. 2016 Dec;23(13):4222-4230. doi: 10.1245/s10434-016-5350-9. Epub 2016 Jun 28.
4
Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.512例阑尾黏液性肿瘤穿孔所致腹膜假黏液瘤患者在肿瘤完全切除及腹腔热灌注化疗后的复发情况及预后
Eur J Surg Oncol. 2015 Mar;41(3):396-9. doi: 10.1016/j.ejso.2014.08.476. Epub 2014 Sep 2.
5
Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.细胞密度对假性黏液瘤腹膜种植患者细胞减灭术和腹腔热灌注化疗后肿瘤学结局的影响。
Ann Surg Oncol. 2018 Jan;25(1):76-82. doi: 10.1245/s10434-017-6214-7. Epub 2017 Nov 6.
6
[Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].[48例腹膜假黏液瘤患者临床及病理特征的预后价值]
Zhonghua Fu Chan Ke Za Zhi. 2013 Aug;48(8):595-601.
7
Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.HIPEC 后腹膜播散性黏液性阑尾肿瘤的组织学预测因子
Ann Surg Oncol. 2018 Mar;25(3):702-708. doi: 10.1245/s10434-017-6310-8. Epub 2017 Dec 27.
8
Management of an inguinal hernia in patients with pseudomyxoma peritonei.腹膜假黏液瘤患者腹股沟疝的管理
Eur J Surg Oncol. 2017 Jun;43(6):1083-1087. doi: 10.1016/j.ejso.2016.12.005. Epub 2017 Jan 6.
9
A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.腹膜假黏液瘤及相关阑尾肿瘤的分类与病理报告共识:国际腹膜表面肿瘤学组(PSOGI)改良德尔菲法的结果
Am J Surg Pathol. 2016 Jan;40(1):14-26. doi: 10.1097/PAS.0000000000000535.
10
[A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].[65例阑尾源性早期腹膜假黏液瘤的单中心临床分析]
Zhonghua Zhong Liu Za Zhi. 2019 Sep 23;41(9):698-702. doi: 10.3760/cma.j.issn.0253-3766.2019.09.010.

引用本文的文献

1
A nomogram prediction model of pseudomyxoma peritonei established based on new prognostic factors of HE stained pathological images analysis.基于 HE 染色病理图像分析的新预后因素建立的腹膜假性黏液瘤预测模型。
Cancer Med. 2024 Mar;13(6):e7101. doi: 10.1002/cam4.7101.
2
Current Status of Treatment among Patients with Appendiceal Tumors-Old Challenges and New Solutions?阑尾肿瘤患者的治疗现状——旧挑战与新解决方案?
Cancers (Basel). 2024 Feb 21;16(5):866. doi: 10.3390/cancers16050866.
3
Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei.
确定用于报告腹膜假黏液瘤临床和放射学数据的最小数据集。
Pleura Peritoneum. 2023 Mar 21;8(1):1-9. doi: 10.1515/pp-2022-0200. eCollection 2023 Mar.
4
Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms.在接受细胞减灭术和腹腔热灌注化疗(CRS/HIPEC)治疗阑尾肿瘤的患者中,无细胞黏蛋白的预后意义。
Langenbecks Arch Surg. 2023 Feb 28;408(1):110. doi: 10.1007/s00423-022-02732-0.
5
Validating the PSOGI classification of peritoneal disease from non-carcinoid epithelial appendiceal neoplasms in the curative and palliative setting: an observational retrospective study.在根治性和姑息性治疗背景下验证非类癌性上皮性阑尾肿瘤腹膜疾病的PSOGI分类:一项观察性回顾性研究
J Gastrointest Oncol. 2022 Apr;13(2):859-870. doi: 10.21037/jgo-21-581.
6
Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study.肿瘤间质比作为预测腹膜假黏液瘤预后的新指标:一项全面的临床病理和免疫组织化学研究。
Diagn Pathol. 2021 Dec 13;16(1):116. doi: 10.1186/s13000-021-01177-1.
7
From the Ronnett to the PSOGI Classification System for Pseudomyxoma Peritonei: A Validation Study.从用于腹膜假黏液瘤的罗内特分类系统到PSOGI分类系统:一项验证研究。
Ann Surg Oncol. 2021 May;28(5):2819-2827. doi: 10.1245/s10434-020-09560-w. Epub 2021 Jan 20.
8
Updated staging and patient outcomes in low-grade appendiceal mucinous neoplasms.低级别阑尾黏液性肿瘤的分期更新及患者预后
Mod Pathol. 2021 Jan;34(1):104-115. doi: 10.1038/s41379-020-0628-7. Epub 2020 Jul 29.
9
[Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix].[阑尾来源腹膜假黏液瘤中肿瘤-间质比例的临床评估]
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Apr 18;52(2):240-246. doi: 10.19723/j.issn.1671-167X.2020.02.008.
10
Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.腹膜表面恶性肿瘤病理评估要点及细胞减灭术标本的大纲式报告——综述与循证指南
Indian J Surg Oncol. 2020 Mar;11(1):101-126. doi: 10.1007/s13193-019-00897-7. Epub 2019 Mar 19.